PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29437146-2	2018	We demonstrate that ITF2357 (givinostat), a clinical-stage inhibitor of histone deacetylase (HDAC) catalytic activity, is efficacious in two distinct murine models of diastolic dysfunction with preserved EF.	givinostat	29-39	histone deacetylase 9	Homo sapiens	93-97	
33517445-6	2021	Remarkably, this STTRN provides insight into the potential mechanism of action for the histone deacetylase (HDAC) inhibitor givinostat, an approved therapy for systemic juvenile idiopathic arthritis (SJIA).	givinostat	124-134	histone deacetylase 9	Homo sapiens	87-106	
33517445-6	2021	Remarkably, this STTRN provides insight into the potential mechanism of action for the histone deacetylase (HDAC) inhibitor givinostat, an approved therapy for systemic juvenile idiopathic arthritis (SJIA).	givinostat	124-134	histone deacetylase 9	Homo sapiens	108-112	
24606390-6	2014	We investigated the effects of a HDAC inhibitor, Givinostat (GVS), on erythropoiesis and haemoglobin synthesis and compared it with sodium butyrate and HC.	givinostat	49-59	histone deacetylase 9	Homo sapiens	33-37	
24606390-6	2014	We investigated the effects of a HDAC inhibitor, Givinostat (GVS), on erythropoiesis and haemoglobin synthesis and compared it with sodium butyrate and HC.	givinostat	61-64	histone deacetylase 9	Homo sapiens	33-37